IO Biotech Inc (IOBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IO Biotech Inc (IOBT) has a cash flow conversion efficiency ratio of -20.283x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($911.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IO Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
IO Biotech Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how IO Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore IO Biotech Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
IO Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IO Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sadot Group Inc.
NASDAQ:SDOT
|
-0.042x |
|
Ivory Properties Group Bhd
KLSE:5175
|
0.629x |
|
Calnex Solutions Plc
LSE:CLX
|
0.111x |
|
MyHotelMatch S.A.
PA:MHM
|
0.019x |
|
Pioneering Technology Corp
V:PTE
|
0.016x |
|
IRWIN NATURALS INC.
F:97X
|
N/A |
|
LeoNovus Inc
V:LTV
|
0.004x |
|
Starwood European Real Estate Finance Ltd
LSE:SWEF
|
0.144x |
Annual Cash Flow Conversion Efficiency for IO Biotech Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of IO Biotech Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market value of IO Biotech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.02 Million | $-82.35 Million | -1.752x | -225.12% |
| 2023-12-31 | $133.16 Million | $-71.74 Million | -0.539x | -25.24% |
| 2022-12-31 | $138.85 Million | $-59.73 Million | -0.430x | -124.28% |
| 2021-12-31 | $211.92 Million | $-40.65 Million | -0.192x | +94.99% |
| 2020-12-31 | $2.60 Million | $-9.96 Million | -3.825x | -163.28% |
| 2019-12-31 | $-1.47 Million | $-8.89 Million | 6.044x | -- |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more